Tango Therapeutics to stop development of cancer therapy (updated)

Tango Therapeutics

23/05/2024 12:29

(Adds share movement in paragraph 2 and details throughout)
       May 23 (Reuters) - Tango Therapeutics  TNGX.O  said on
Thursday it would stop the development of its experimental
cancer therapy due to liver toxicity experienced by patients in
an early-to-mid stage trial.
    Shares of the Boston-based cancer therapy developer fell
5.4% in premarket trading.
    The therapy, TNG348, was being tested alone as well as in
combination with Lynparza — which is jointly developed by
AstraZeneca  AZN.L  and Merck  MRK.N  — in patients whose cancer
expressed certain types of mutations.
    Serious liver function abnormalities were observed in
patients remaining on study longer than eight weeks, Tango said,
adding that no patient had yet received a combination of TNG348
and Lynparza.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi
Majumdar)
 ((Mariam.ESunny@thomsonreuters.com;))